# Deep Research Report: moonshot/kimi-k2-turbo-preview-web-search
**Status:** ✅ Success | **Attempts:** 1/5 | **Run ID:** 7634e5a8 | **Time:** 16.13s | **Cost:** $0.02472
--------------------------------------------------------------------------------

Predicting the clinical efficacy of multi-target antipsychotics is a complex process that involves integrating **dose-response data from animal models** with **human receptor affinity profiles**. This translational approach aims to estimate therapeutic doses and receptor occupancy (RO) in humans, which are critical for antipsychotic efficacy and side-effect profiling. Here's how this is typically done:

---

### 1. **Receptor Affinity Profiling in Humans**
- **In vitro binding assays** determine the affinity (Ki or Kd) of a drug and its metabolites for key human CNS receptors (e.g., D2, 5-HT1A, 5-HT2A).
- These affinities are used to estimate **receptor occupancy (RO)** at a given drug concentration in the brain.

---

### 2. **Dose-Response Studies in Animal Models**
- Behavioral models (e.g., apomorphine-induced climbing, ketamine-induced hyperlocomotion) are used to assess antipsychotic-like activity.
- **ED50 values** (effective dose producing 50% of the maximal effect) are derived from dose-response curves.
- These models also help assess **side-effect liabilities**, such as catalepsy (a proxy for extrapyramidal symptoms).

---

### 3. **Translation from Animal to Human**
- **Physiologically-based pharmacokinetic (PBPK) modeling** is used to simulate human brain exposure based on animal data.
- RO is estimated using the drug’s unbound plasma or brain concentration and its receptor affinity.
- The goal is to identify **doses that achieve therapeutic RO (typically 60–80% for D2)** without excessive occupancy at off-target receptors.

---

### 4. **Balancing Multi-Target Effects**
- Multi-target antipsychotics often combine **D2 antagonism** with **5-HT1A agonism** and **5-HT2A antagonism**.
- The **net therapeutic effect** is predicted by integrating RO at each receptor:
  - **D2**: Antipsychotic efficacy (but high RO → side effects)
  - **5-HT1A**: Potential anxiolytic and cognitive benefits
  - **5-HT2A**: May reduce EPS and improve negative symptoms
- **Catalepsy thresholds** in animals are used to predict EPS risk in humans.

---

### 5. **Modeling and Simulation**
- **PBPK-RO models** simulate human brain exposure and RO for both parent drug and active metabolites.
- These models are validated against clinical PET data when available.
- They help **optimize dose selection** for clinical trials by predicting the **lowest effective dose** with minimal side effects.

---

### Summary
The clinical efficacy of multi-target antipsychotics is predicted by:
- Measuring **human receptor affinities**
- Determining **dose-response relationships** in animal models
- Using **PBPK modeling** to translate animal doses to human exposure
- Estimating **receptor occupancy** at therapeutic doses
- **Balancing multi-receptor effects** to maximize efficacy and minimize side effects

This integrative approach allows for **quantitative prediction** of clinical outcomes and supports **rational dose selection** early in drug development.

## Annotations


## Sources
